Killing Effect of A CD7 Chimeric Antigen Receptor-Modified NK-92MI Cell Line on CD7-Positive Hematological Malignant Cells.
10.19746/j.cnki.issn.1009-2137.2020.04.049
- Author:
Xin-Ying ZHU
1
;
Xin LIU
2
;
Xing-Bing WANG
1
;
An-You WANG
1
;
Min WANG
3
;
Na-Na LIU
3
;
Feng-Tao YOU
3
;
Gui-Fang PAN
3
;
Lin YANG
3
Author Information
1. Department of Hematology, Anhui Provincial Hospital, Provincial Hospital Affiliated to Anhui Medical University, Hefei 230001, Anhui Province, China.
2. Department of Hematology, Anhui Provincial Hospital, Provincial Hospital Affiliated to Anhui Medical University, Hefei 230001, Anhui Province, China,E-mail: lxinahf@sina.com.
3. PersonGen-Anke Cell Technology Co., Ltd, Hefei 230088, Anhui Province, China.
- Publication Type:Journal Article
- MeSH:
Cell Line, Tumor;
Humans;
Killer Cells, Natural;
Leukemia, Myeloid, Acute;
Receptors, Chimeric Antigen;
T-Lymphocytes
- From:
Journal of Experimental Hematology
2020;28(4):1367-1375
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the killing effect of NK-92MI cells modified by chimeric antigen receptor (CD7-CAR) and specifically targeting CD7 to CD7 hematological malignant cells.
METHODS:Three types of hematological malignant tumor cells, including 5 cases of CD7 acute T-lymphoblastic leukemia (T-ALL), 10 cases of acute myeloid leukemia (AML) and 6 cases of T-cell lymphoma were collected, centrifuged, cultured and used to detect the expression levels of tumor cell surface targets; 7-AAD, CD56-APC, CD3-FITC, IgG Fc-PE flow cytometry were used to detected the transfection efficiency of NK-92MI and CD7-CAR-NK-92MI cells, killing efficiencies of CD7-CAR-NK-92MI cells to CD7 hematological tumor cells in vitro were determined by flow cytometry using PE Annexin V Apoptosis Detection Kit. Secretion differences of NK-92MI and CD7-CAR-NK-92MI cytokines interleukin (IL)-2, interferon (IFN)-γ, and granzyme B detection were estimated by using CBA kit.
RESULTS:The killing efficiencies of CD7-CAR-modified NK-92MI cells to CD7 T-ALL, AML, T-cell lymphoma tumor cells were significantly higher than those of NK-92MI cells without genetical modification. The difference showed statistically significant (P＜0.05). The level of IFN-γ and granzyme B were significantly increased among cytokines secreted by CD7-CAR-modified NK-92MI cells as compared with those of NK-92MI cells without genetical modification (P＜0.05) .
CONCLUSION:CD7-CAR-modified NK-92MI cells have significantly improved killing efficiency against CD7 T-ALL, AML and T lymphoma cells, and shows specific targeting effects, which provides a clinical basis for the treatment of CD7 hematological malignancies.
